Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MultipleMS prospective cohort in newly diagnosed MS and CIS
2017-002634-24Phase 4Completed
- Sponsor
- Karolinska Institutet
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab, natalizumab, dimethyl fumarate, fingolimod, glatiramer acetate and 5 more in multiple sclerosis (MS) and clinically isolated syndrome (CIS), sponsored by Karolinska Institutet. Primary endpoint: Association of MultipleMS risk score with new and enlarging T2 lesions. Started Jul 2017; status: completed.
02
Drugs
rituximabnatalizumabdimethyl fumaratefingolimodglatiramer acetate
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on 2017-002634-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002634-24.